AI Engines For more Details: Perplexity Kagi Labs You
Antineoplastic Activity: Daunorubicin hydrochloride exerts its therapeutic effects primarily through its potent antineoplastic (anti-cancer) activity. It works by inhibiting DNA and RNA synthesis in rapidly dividing cancer cells, leading to cell cycle arrest and apoptosis (programmed cell death). This helps to slow down or stop the growth of cancer cells and shrink tumors.
Treatment of Leukemia: Daunorubicin hydrochloride is commonly used as part of combination chemotherapy regimens for the treatment of leukemia, particularly acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It may be used as induction therapy to achieve remission, consolidation therapy to prevent disease recurrence, or as part of salvage therapy for relapsed or refractory leukemia.
Solid Tumors: In addition to leukemia, daunorubicin hydrochloride may also be used in the treatment of certain solid tumors, including sarcomas, breast cancer, and lung cancer. It may be used alone or in combination with other chemotherapy drugs, surgery, radiation therapy, or targeted therapies, depending on the specific type and stage of cancer.
Dosage and Administration: Daunorubicin hydrochloride is typically administered intravenously (IV) by a healthcare professional in a hospital or clinic setting. The dosage and schedule of administration depend on factors such as the type of cancer being treated, the patient's overall health, and their response to treatment. Daunorubicin hydrochloride is often given in cycles, with rest periods between doses to allow the body to recover from side effects.
Side Effects: Despite its effectiveness in treating cancer, daunorubicin hydrochloride can cause a range of side effects, some of which may be serious or life-threatening. Common side effects may include nausea, vomiting, diarrhea, hair loss, fatigue, mouth sores, and bone marrow suppression (resulting in low blood cell counts). It may also cause cardiotoxicity, leading to heart failure or arrhythmias, particularly at higher doses or with long-term use.
Cardioprotection: Cardiotoxicity is a well-known side effect of anthracycline chemotherapy drugs like daunorubicin hydrochloride. To mitigate the risk of cardiotoxicity, cardioprotective measures such as monitoring cardiac function (e.g., echocardiography), limiting cumulative doses of daunorubicin, and administering dexrazoxane (a cardioprotective agent) may be used in certain patients, particularly those at higher risk of cardiac complications.
Monitoring: Patients receiving daunorubicin hydrochloride therapy require close monitoring by their healthcare team to assess treatment response, manage side effects, and monitor for potential complications such as cardiotoxicity or bone marrow suppression. Blood tests, imaging studies, and cardiac assessments may be performed regularly to evaluate treatment efficacy and safety.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.6 | 0.9 | -0.5 |
| ADHD | 5.1 | 0.9 | 4.67 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 2.5 | 0.36 |
| Allergies | 6.9 | 3.5 | 0.97 |
| Allergy to milk products | 1.5 | 1.6 | -0.07 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.4 | 7.4 | -0.16 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 3.2 | 0.5 | 5.4 |
| Ankylosing spondylitis | 4.1 | 1.8 | 1.28 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.6 | 1.6 | |
| Asthma | 5.7 | 2 | 1.85 |
| Atherosclerosis | 2.2 | 2.5 | -0.14 |
| Atrial fibrillation | 3.8 | 2.8 | 0.36 |
| Autism | 10.5 | 9.8 | 0.07 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.2 | 2.2 | |
| Bipolar Disorder | 2.1 | 1.4 | 0.5 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.7 | 0.7 | |
| Cancer (General) | 0.6 | 3.4 | -4.67 |
| Carcinoma | 4.7 | 2.6 | 0.81 |
| Celiac Disease | 2.8 | 3.2 | -0.14 |
| Cerebral Palsy | 1.1 | 1.3 | -0.18 |
| Chronic Fatigue Syndrome | 5.8 | 6.8 | -0.17 |
| Chronic Kidney Disease | 4.9 | 2.6 | 0.88 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.2 | 1.7 | 0.29 |
| Chronic Urticaria (Hives) | 1.2 | 1.2 | 0 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.6 | 1.6 | 1.25 |
| Colorectal Cancer | 8.6 | 2.3 | 2.74 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.5 | 2.7 | -0.08 |
| COVID-19 | 10.7 | 13.8 | -0.29 |
| Crohn's Disease | 8.8 | 5.8 | 0.52 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.7 | 1.9 | -1.71 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 3.2 | 1.4 | 1.29 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 12.2 | 9.6 | 0.27 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2 | 2.6 | -0.3 |
| Endometriosis | 3 | 1.9 | 0.58 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | 0 |
| Epilepsy | 3.5 | 1.7 | 1.06 |
| erectile dysfunction | 2.6 | 0.3 | 7.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.4 | 4.9 | 0.31 |
| gallstone disease (gsd) | 3.6 | 1.1 | 2.27 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.1 | 1.2 | 0.75 |
| Generalized anxiety disorder | 2.9 | 2.5 | 0.16 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.8 | 1.63 |
| Graves' disease | 1.6 | 3 | -0.88 |
| Gulf War Syndrome | 0.9 | 1.5 | -0.67 |
| Halitosis | 1.5 | 0.3 | 4 |
| Hashimoto's thyroiditis | 3.6 | 1.5 | 1.4 |
| Heart Failure | 4.9 | 1.9 | 1.58 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 1.5 | 0.6 | 1.5 |
| hypercholesterolemia (High Cholesterol) | 0.6 | 0.6 | |
| hyperglycemia | 1.3 | 1.1 | 0.18 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.7 | 6 | -0.28 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 3.1 | 0.9 | 2.44 |
| IgA nephropathy (IgAN) | 1.9 | 4.6 | -1.42 |
| Inflammatory Bowel Disease | 10.4 | 9.6 | 0.08 |
| Insomnia | 2.2 | 2.1 | 0.05 |
| Intelligence | 1.5 | 0.6 | 1.5 |
| Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
| Irritable Bowel Syndrome | 7.6 | 5 | 0.52 |
| ischemic stroke | 2.5 | 1.7 | 0.47 |
| Liver Cirrhosis | 7 | 3.2 | 1.19 |
| Long COVID | 8 | 8.5 | -0.06 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.2 | 1 | 0.2 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.5 | 3.2 |
| Metabolic Syndrome | 7.6 | 7.9 | -0.04 |
| Mood Disorders | 11.4 | 8.1 | 0.41 |
| multiple chemical sensitivity [MCS] | 0.9 | 0.1 | 8 |
| Multiple Sclerosis | 7.6 | 7 | 0.09 |
| Multiple system atrophy (MSA) | 1.2 | 0.7 | 0.71 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.1 | -9.33 |
| Neuropathy (all types) | 0.7 | 2.8 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6 | 4.8 | 0.25 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 11 | 8.9 | 0.24 |
| obsessive-compulsive disorder | 6.2 | 4.2 | 0.48 |
| Osteoarthritis | 3.3 | 1.2 | 1.75 |
| Osteoporosis | 2.2 | 1.3 | 0.69 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 8.1 | 8 | 0.01 |
| Polycystic ovary syndrome | 7.9 | 2.9 | 1.72 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 0.9 | 1.7 | -0.89 |
| Primary sclerosing cholangitis | 2.1 | 3.2 | -0.52 |
| Psoriasis | 3.2 | 3.4 | -0.06 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 8.8 | 4.4 | 1 |
| Rosacea | 1.2 | 1 | 0.2 |
| Schizophrenia | 6.1 | 2.8 | 1.18 |
| scoliosis | 0.4 | 0.9 | -1.25 |
| Sjögren syndrome | 2.3 | 3.2 | -0.39 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.3 | 1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.5 | 0.6 | 1.5 |
| Stress / posttraumatic stress disorder | 2.8 | 2.7 | 0.04 |
| Systemic Lupus Erythematosus | 4.3 | 2.4 | 0.79 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.9 | 4.4 | -0.13 |
| Type 2 Diabetes | 9.2 | 7.8 | 0.18 |
| Ulcerative colitis | 6.3 | 7.4 | -0.17 |
| Unhealthy Ageing | 6.2 | 2.4 | 1.58 |
| Vitiligo | 2.5 | 1.5 | 0.67 |
